Working… Menu
Trial record 23 of 2033 for:    doxil

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01715168
Recruitment Status : Unknown
Verified January 2015 by Azaya Therapeutics, Inc..
Recruitment status was:  Active, not recruiting
First Posted : October 26, 2012
Last Update Posted : January 15, 2015
Information provided by (Responsible Party):
Azaya Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : October 2015
Estimated Study Completion Date : December 2015